Charles River Laboratories (CRL) Tops Q4 EPS by 12c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $288.50 -1.65%
Revenue Growth %: -4.3%
Financial Fact:
Interest income: 523K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Interest income: 523K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.66, $0.12 better than the analyst estimate of $2.54. Revenue for the quarter came in at $1 billion versus the consensus estimate of $985.18 million.
GUIDANCE:
Charles River Laboratories sees FY2025 EPS of $9.10-$9.60, versus the consensus of $9.60.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Starts Shake Shack (SHAK) at Outperform
- Roth/MKM Downgrades eGain Corporation (EGAN) to Neutral
- JPMorgan Upgrades Yangzijiang Shipbuilding (YZJSGD:SP) (YSHLF) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
